GH Research (GHRS) Competitors

GH Research (NASDAQ:GHRS) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Which has more volatility & risk, GHRS or APLS?

GH Research has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Which has higher valuation and earnings, GHRS or APLS?

GH Research has higher earnings, but lower revenue than Apellis Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$35.59M	-$0.79	-15.82
Apellis Pharmaceuticals	$775.84M	3.12	-$528.63M	-$1.79	-10.77

Do institutionals and insiders hold more shares of GHRS or APLS?

56.9% of GH Research shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer GHRS or APLS?

In the previous week, Apellis Pharmaceuticals had 7 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 4 mentions for GH Research. GH Research's average media sentiment score of 0.45 beat Apellis Pharmaceuticals' score of 0.42 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apellis Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate GHRS or APLS?

GH Research presently has a consensus target price of $32.00, suggesting a potential upside of 156.00%. Apellis Pharmaceuticals has a consensus target price of $40.05, suggesting a potential upside of 107.74%. Given GH Research's stronger consensus rating and higher probable upside, research analysts clearly believe GH Research is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.62

Is GHRS or APLS more profitable?

GH Research has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. GH Research's return on equity of -20.29% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.29%	-19.49%
Apellis Pharmaceuticals	-34.97%	-103.11%	-28.96%

Does the MarketBeat Community prefer GHRS or APLS?

Apellis Pharmaceuticals received 318 more outperform votes than GH Research when rated by MarketBeat users. However, 77.27% of users gave GH Research an outperform vote while only 66.29% of users gave Apellis Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
GH Research	Outperform Votes 34 77.27%	Underperform Votes 10 22.73%
Apellis Pharmaceuticals	Outperform Votes 352 66.29%	Underperform Votes 179 33.71%

Summary

GH Research beats Apellis Pharmaceuticals on 11 of the 18 factors compared between the two stocks.